NGENLA (somatrogon-ghla) injection, for subcutaneous use Initial U.S. Approval: 2023

Ngenla is a medicine used to treat children and adolescents who are not growing at the normal rate as a result of growth hormone deficiency (lack of natural growth hormone). It is given to patients from 3 years of age. Ngenla contains the active substance somatrogon.

Brand Name: NGENLA
Generic Name: somatrogon-ghla
Strength: Injection:
• 24 mg/1.2 mL (20 mg/mL) single-patient-use prefilled pen that delivers a dose
in 0.2 mg increments.
• 60 mg/1.2 mL (50 mg/mL) single-patient-use prefilled pen that delivers a dose
in 0.5 mg increments..
Manufacturer: Pfizer Inc
Approved By: EMA, USFDA

Source Details: Patient Information

IPN, New Delhi can facilitate patient to import of “NGENLA (somatrogon-ghla) injection” in small quantities for personal use. For this applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP). If you have any question, please email IPN healthcare Support Team for NGENLA (somatrogon-ghla) injection price list or cost in India. on Mr. Tarun:- +91 9891 296 838 / Mr. Neeraj:- +91 9811 747 774.

read more